vs
Side-by-side financial comparison of Kentucky First Federal Bancorp (KFFB) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $2.8M, roughly 1.9× Kentucky First Federal Bancorp). Kentucky First Federal Bancorp runs the higher net margin — 10.7% vs -507.8%, a 518.5% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs 28.3%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs 24.0%).
Kentucky First Federal Bancorp is a U.S. regional bank holding company based in Kentucky. It offers retail and commercial banking services including deposits, mortgage loans, consumer lending and small business financing, serving local individual customers and small-to-medium enterprises across its Kentucky operating regions.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
KFFB vs TSHA — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.8M | $5.5M |
| Net Profit | $304.0K | $-27.9M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | -516.0% |
| Net Margin | 10.7% | -507.8% |
| Revenue YoY | 28.3% | 171.3% |
| Net Profit YoY | 2238.5% | -48.3% |
| EPS (diluted) | $0.04 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8M | $5.5M | ||
| Q3 25 | $2.7M | $0 | ||
| Q2 25 | $2.4M | $2.0M | ||
| Q1 25 | $2.2M | $2.3M | ||
| Q4 24 | $2.2M | $2.0M | ||
| Q3 24 | $2.0M | $1.8M | ||
| Q2 24 | $2.0M | $1.1M | ||
| Q1 24 | $1.8M | $3.4M |
| Q4 25 | $304.0K | $-27.9M | ||
| Q3 25 | $344.0K | $-32.7M | ||
| Q2 25 | $176.0K | $-26.9M | ||
| Q1 25 | $7.0K | $-21.5M | ||
| Q4 24 | $13.0K | $-18.8M | ||
| Q3 24 | $-15.0K | $-25.5M | ||
| Q2 24 | $-1.1M | $-20.9M | ||
| Q1 24 | $-107.0K | $-24.1M |
| Q4 25 | 14.1% | -516.0% | ||
| Q3 25 | 17.0% | — | ||
| Q2 25 | 10.3% | -1347.1% | ||
| Q1 25 | 0.7% | -930.5% | ||
| Q4 24 | 0.3% | -985.8% | ||
| Q3 24 | -1.0% | -1448.4% | ||
| Q2 24 | -58.7% | -1915.4% | ||
| Q1 24 | -7.9% | -713.3% |
| Q4 25 | 10.7% | -507.8% | ||
| Q3 25 | 12.9% | — | ||
| Q2 25 | 7.6% | -1353.6% | ||
| Q1 25 | 0.3% | -935.2% | ||
| Q4 24 | 0.6% | -929.0% | ||
| Q3 24 | -0.7% | -1427.5% | ||
| Q2 24 | -56.7% | -1882.0% | ||
| Q1 24 | -5.8% | -705.4% |
| Q4 25 | $0.04 | $-0.08 | ||
| Q3 25 | $0.04 | $-0.09 | ||
| Q2 25 | $0.02 | $-0.09 | ||
| Q1 25 | $0.00 | $-0.08 | ||
| Q4 24 | $0.00 | $-0.07 | ||
| Q3 24 | $0.00 | $-0.10 | ||
| Q2 24 | $-0.13 | $-0.09 | ||
| Q1 24 | $-0.01 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.7M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $49.1M | $246.9M |
| Total Assets | $375.3M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.7M | $319.8M | ||
| Q3 25 | $14.6M | $297.3M | ||
| Q2 25 | $19.5M | $312.8M | ||
| Q1 25 | $27.8M | $116.6M | ||
| Q4 24 | $21.0M | $139.0M | ||
| Q3 24 | $17.3M | $157.7M | ||
| Q2 24 | $18.3M | $172.7M | ||
| Q1 24 | $15.4M | $124.0M |
| Q4 25 | $49.1M | $246.9M | ||
| Q3 25 | $48.8M | $219.0M | ||
| Q2 25 | $48.4M | $248.7M | ||
| Q1 25 | $48.2M | $55.1M | ||
| Q4 24 | $48.1M | $71.5M | ||
| Q3 24 | $48.2M | $88.8M | ||
| Q2 24 | $48.0M | $108.9M | ||
| Q1 24 | $49.0M | $53.8M |
| Q4 25 | $375.3M | $343.3M | ||
| Q3 25 | $366.5M | $316.6M | ||
| Q2 25 | $371.2M | $333.3M | ||
| Q1 25 | $380.7M | $138.4M | ||
| Q4 24 | $374.2M | $160.4M | ||
| Q3 24 | $375.6M | $180.2M | ||
| Q2 24 | $375.0M | $200.4M | ||
| Q1 24 | $369.1M | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-303.0K | $-26.7M |
| Free Cash FlowOCF − Capex | $-367.0K | — |
| FCF MarginFCF / Revenue | -12.9% | — |
| Capex IntensityCapex / Revenue | 2.3% | — |
| Cash ConversionOCF / Net Profit | -1.00× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-377.0K | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-303.0K | $-26.7M | ||
| Q3 25 | $450.0K | $-24.2M | ||
| Q2 25 | $-86.0K | $-20.2M | ||
| Q1 25 | $-155.0K | $-22.0M | ||
| Q4 24 | $1.4M | $-18.3M | ||
| Q3 24 | $-1.4M | $-21.6M | ||
| Q2 24 | $-1.5M | $-21.5M | ||
| Q1 24 | $-176.0K | $-19.8M |
| Q4 25 | $-367.0K | — | ||
| Q3 25 | $445.0K | $-24.3M | ||
| Q2 25 | $-235.0K | — | ||
| Q1 25 | $-220.0K | — | ||
| Q4 24 | $1.4M | $-18.3M | ||
| Q3 24 | $-1.4M | $-21.6M | ||
| Q2 24 | $-1.5M | $-21.7M | ||
| Q1 24 | $-191.0K | $-19.9M |
| Q4 25 | -12.9% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | -9.7% | — | ||
| Q1 25 | -9.9% | — | ||
| Q4 24 | 61.8% | -905.5% | ||
| Q3 24 | -70.2% | -1210.9% | ||
| Q2 24 | -77.7% | -1951.9% | ||
| Q1 24 | -10.4% | -584.5% |
| Q4 25 | 2.3% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 6.2% | — | ||
| Q1 25 | 2.9% | — | ||
| Q4 24 | 3.7% | 0.1% | ||
| Q3 24 | 0.1% | 2.0% | ||
| Q2 24 | 3.4% | 18.1% | ||
| Q1 24 | 0.8% | 4.1% |
| Q4 25 | -1.00× | — | ||
| Q3 25 | 1.31× | — | ||
| Q2 25 | -0.49× | — | ||
| Q1 25 | -22.14× | — | ||
| Q4 24 | 111.31× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
